{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.9","value":"601.5"},{"groupId":"OG001","spread":"1.5","value":"1414.9"},{"groupId":"OG002","spread":"34.7","value":"1536.1"},{"groupId":"OG003","spread":"44.9","value":"2793.5"},{"groupId":"OG004","spread":"37.8","value":"5126.6"},{"groupId":"OG005","spread":"10.9","value":"7475.8"},{"groupId":"OG006","spread":"39.5","value":"9531.2"},{"groupId":"OG007","spread":"27.8","value":"12159.8"},{"groupId":"OG008","spread":"27.4","value":"16346.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"8"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.5","value":"580.6"},{"comment":"The measure was only collected for one participant.","groupId":"OG001","spread":"NA","value":"2160.0"},{"groupId":"OG002","spread":"46.0","value":"2413.2"},{"groupId":"OG003","spread":"45.6","value":"4149.8"},{"groupId":"OG004","spread":"40.2","value":"4409.6"},{"groupId":"OG005","spread":"23.8","value":"7571.7"},{"groupId":"OG006","spread":"23.6","value":"11906.8"},{"groupId":"OG007","spread":"36.0","value":"12917.1"},{"groupId":"OG008","spread":"154.2","value":"25955.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"5"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3","value":"566.5"},{"groupId":"OG001","spread":"46.7","value":"1724.4"},{"groupId":"OG002","spread":"57.4","value":"2406.6"},{"groupId":"OG003","spread":"54.5","value":"3712.8"},{"groupId":"OG004","spread":"18.7","value":"4359.1"},{"groupId":"OG005","spread":"21.1","value":"6686.2"},{"groupId":"OG006","spread":"42.2","value":"14497.6"},{"groupId":"OG007","spread":"36.0","value":"12208.5"},{"groupId":"OG008","spread":"260.2","value":"31491.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"3"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.7","value":"603.2"},{"groupId":"OG001","spread":"61.3","value":"1334.6"},{"groupId":"OG002","spread":"36.3","value":"2128.8"},{"groupId":"OG003","spread":"27.5","value":"3510.7"},{"groupId":"OG004","spread":"28.6","value":"4409.6"},{"groupId":"OG005","spread":"24.9","value":"7343.5"},{"groupId":"OG006","spread":"11.0","value":"12218.5"},{"groupId":"OG007","spread":"31.4","value":"15342.7"},{"comment":"The measure was only collected for one participant.","groupId":"OG008","spread":"NA","value":"18300.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"1"}],"units":"Participants"}],"title":"Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"8"}],"units":"Participants"}],"description":"This is the maximum observed plasma concentration (Cmax) observed after administration of KZR-261 in Cycle 1 (Days 1 and 15) and Cycle 2 (Days 1 and 15). The PK parameters were calculated using all timepoints at which the concentration was measured, ie. predose, 15 minutes post start of infusion, end of infusion, and 5, 15, 30 minutes, 1, 2, 4, 6, 24, 48, and 96 hours post infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261.","id":"OG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261.","id":"OG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261.","id":"OG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261.","id":"OG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261.","id":"OG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261.","id":"OG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261.","id":"OG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261.","id":"OG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261.","id":"OG008","title":"Dose 9"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analyses were performed for all subjects in the PK population (all subjects that received at least one dose plasma KZR-261 concentration measurement during Cycles 1 and 2 of treatment).","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day 1, Cycle 1: Day 15, Cycle 2: Day 1, and Cycle 2: Day 15","title":"Maximum Plasma Concentration of KZR-261 (Part 1)","type":"PRIMARY","unitOfMeasure":"ng/mL"}